G1 Therapeutics

$10.65 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Subscribe

About G1 Therapeutics

G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing small-molecule therapies for the treatment of cancer. Its two clinical-stage candidates are trilaciclib (G1T28) and G1T38, which are potent, selective inhibitors of the validated kinase targets CDK4/6. Trilaciclib and G1T38 are designed to be combined and enhance the anti-tumor activity of current therapies. It is also developing G1T48, an oral selective estrogen receptor degrader (SERD) for the treatment of breast cancer. The Company is evaluating trilaciclib in three Phase II clinical trials. G1T38 is being evaluated in combination with Faslodex in a Phase I b/II a trial for patients with estrogen receptor-positive, HER2-negative breast cancer.

Stock Analysis

last close $10.65
1-mo return -34.1%
3-mo return -29.9%
avg daily vol. 935.42T
52-week high 37.07
52-week low 10.51
market cap. $553M
forward pe -
annual div. -
roe -71.1%
ltg forecast -
dividend yield -
annual rev. $42M
inst own. 74.9%
baraka

Subscribe now for daily local and international financial news

Subscribe